Article: AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleAXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma
AuthorsXu, MZ4 5
Chan, SW2
Liu, AM4 6
Wong, KF4 6
Fan, ST4
Chen, J5
Poon, RT4
Zender, L1
Lowe, SW3
Hong, W2
Luk, JM4 5 6
KeywordsAXL receptor kinase
cancer signaling
HCC
hepatocellular carcinoma
Hippo pathway
YAP1 oncogene
Issue Date2011
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/onc
CitationOncogene, 2011, v. 30 n. 10, p. 1229-1240 [How to Cite?]
DOI: http://dx.doi.org/10.1038/onc.2010.504
AbstractYes-associated protein (YAP) is a downstream effector of the Hippo signaling pathway, which controls organ expansion and tissue development. We have recently defined the tumorigenic potential and clinical significance of the YAP1 oncogene in human hepatocellular carcinoma (HCC). The present study aims to define the tumorigenic properties of YAP in HCC and elucidate the related downstream signaling mechanism. In a gain-of-function study, we demonstrated that ectopic increased expression of YAP in the immortalized non-tumorigenic hepatocyte cell line MIHA confers tumorigenic and metastatic potentials, as evidenced by (1) enhanced aptitudes in cell viability, anchorage-independent growth, migration and invasion; (2) tumor formation in a xenograft mouse model; and (3) induction of HCC biomarker α-fetoprotein and activation of mitogen-activated protein kinase. Furthermore, we have identified AXL, a receptor tyrosine kinase, as a key downstream target that drives YAP-dependent oncogenic functions. RNAi-mediated knockdown of AXL expression decreased the ability of YAP-expressing MIHA cells and of the primary HCC cell line to proliferate and invade. These results indicate that AXL is a mediator of YAP-dependent oncogenic activities and implicates it as a potential therapeutic target for HCC. © 2011 Macmillan Publishers Limited All rights reserved.
ISSN0950-9232
2011 Impact Factor: 6.373
2011 SCImago Journal Rankings: 1.216
DOIhttp://dx.doi.org/10.1038/onc.2010.504
ISI Accession Number IDWOS:000288202400009
Funding AgencyGrant Number
Biomedical Research Grants Council of Singapore
National University Cancer Institute (NCIS) Centre
National Natural Science Foundation of China81000880
National Cancer Institute of NIHCA13106
A*STAR
Funding Information:

Sources of support: The work was supported by grants to JML from the Biomedical Research Grants Council of Singapore and by the National University Cancer Institute (NCIS) Centre Grant; WH was supported by the A*STAR and MX by the National Natural Science Foundation of China (Grant No. 81000880). SWL is an investigator in the Howard Hughes Medical Institute and Dr Lowe's work is supported by a program grant (CA13106) from the National Cancer Institute of NIH.

PubMed Central IDPMC3330262
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorXu, MZ
dc.contributor.authorChan, SW
dc.contributor.authorLiu, AM
dc.contributor.authorWong, KF
dc.contributor.authorFan, ST
dc.contributor.authorChen, J
dc.contributor.authorPoon, RT
dc.contributor.authorZender, L
dc.contributor.authorLowe, SW
dc.contributor.authorHong, W
dc.contributor.authorLuk, JM
dc.date.accessioned2011-07-27T01:36:54Z
dc.date.available2011-07-27T01:36:54Z
dc.date.issued2011
dc.description.abstractYes-associated protein (YAP) is a downstream effector of the Hippo signaling pathway, which controls organ expansion and tissue development. We have recently defined the tumorigenic potential and clinical significance of the YAP1 oncogene in human hepatocellular carcinoma (HCC). The present study aims to define the tumorigenic properties of YAP in HCC and elucidate the related downstream signaling mechanism. In a gain-of-function study, we demonstrated that ectopic increased expression of YAP in the immortalized non-tumorigenic hepatocyte cell line MIHA confers tumorigenic and metastatic potentials, as evidenced by (1) enhanced aptitudes in cell viability, anchorage-independent growth, migration and invasion; (2) tumor formation in a xenograft mouse model; and (3) induction of HCC biomarker α-fetoprotein and activation of mitogen-activated protein kinase. Furthermore, we have identified AXL, a receptor tyrosine kinase, as a key downstream target that drives YAP-dependent oncogenic functions. RNAi-mediated knockdown of AXL expression decreased the ability of YAP-expressing MIHA cells and of the primary HCC cell line to proliferate and invade. These results indicate that AXL is a mediator of YAP-dependent oncogenic activities and implicates it as a potential therapeutic target for HCC. © 2011 Macmillan Publishers Limited All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationOncogene, 2011, v. 30 n. 10, p. 1229-1240 [How to Cite?]
DOI: http://dx.doi.org/10.1038/onc.2010.504
dc.identifier.citeulike8297310
dc.identifier.doihttp://dx.doi.org/10.1038/onc.2010.504
dc.identifier.epage1240
dc.identifier.hkuros187696
dc.identifier.isiWOS:000288202400009
Funding AgencyGrant Number
Biomedical Research Grants Council of Singapore
National University Cancer Institute (NCIS) Centre
National Natural Science Foundation of China81000880
National Cancer Institute of NIHCA13106
A*STAR
Funding Information:

Sources of support: The work was supported by grants to JML from the Biomedical Research Grants Council of Singapore and by the National University Cancer Institute (NCIS) Centre Grant; WH was supported by the A*STAR and MX by the National Natural Science Foundation of China (Grant No. 81000880). SWL is an investigator in the Howard Hughes Medical Institute and Dr Lowe's work is supported by a program grant (CA13106) from the National Cancer Institute of NIH.

dc.identifier.issn0950-9232
2011 Impact Factor: 6.373
2011 SCImago Journal Rankings: 1.216
dc.identifier.issue10
dc.identifier.openurl
dc.identifier.pmcidPMC3330262
dc.identifier.pmid21076472
dc.identifier.scopuseid_2-s2.0-79952532529
dc.identifier.spage1229
dc.identifier.urihttp://hdl.handle.net/10722/135547
dc.identifier.volume30
dc.languageeng
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/onc
dc.publisher.placeUnited Kingdom
dc.relation.ispartofOncogene
dc.relation.referencesReferences in Scopus
dc.subject.meshCarcinoma, Hepatocellular - genetics - metabolism
dc.subject.meshCell Transformation, Neoplastic - genetics - metabolism
dc.subject.meshLiver Neoplasms - genetics - metabolism
dc.subject.meshNuclear Proteins - genetics - metabolism
dc.subject.meshProto-Oncogene Proteins - genetics - metabolism
dc.subjectAXL receptor kinase
dc.subjectcancer signaling
dc.subjectHCC
dc.subjecthepatocellular carcinoma
dc.subjectHippo pathway
dc.subjectYAP1 oncogene
dc.titleAXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma
dc.typeArticle
Author Affiliations
  1. Helmholtz Centre for Infection Research (HZI)
  2. Institute of Molecular and Cell Biology, A-Star, Singapore
  3. Howard Hughes Medical Institute
  4. The University of Hong Kong
  5. Nanjing Medical University
  6. National University of Singapore